IOVANCE Biotherapeutics

Maria Fardis, Ph.D., CEO
San Carlos, CA
(NASDAQ: IOVA)
IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL). IOVANCE is conducting four Phase II clinical trials to assess the efficacy and safety of autologous Tumor Infiltrating Lymphocytes for treatment of patients with Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-Small Cell Lung Cancer (NSCLC), and Cervical Cancer.
www.iovance.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions